ArticleThe Journal of clinical endocrinology and metabolism2014
Medullary thyroid cancer in the era of tyrosine kinase inhibitors: to treat or not to treat--and with which drug--those are the questions.
Article in The Journal of clinical endocrinology and metabolism, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 55 citations in OpenAlex.
- Systemic therapies for medullary thyroid carcinoma: state of the art.Therapeutic advances in endocrinology and metabolism · 2025Review
- Systemic Therapies for Advanced Medullary Thyroid Carcinoma.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2025Review
- Spontaneous and Treatment-Related Changes of Serum Calcitonin in Medullary Thyroid Cancer: Long-Term Experience in a Patient With Multiple Endocrine Neoplasia Type 2B.JCO precision oncology · 2024Article
- The Evolving Treatment Landscape of Medullary Thyroid Cancer.Current treatment options in oncology · 2023Review
- Metastatic medullary thyroid carcinoma (MTC): disease course, treatment modalities and factors predisposing for drug resistance.Endocrine · 2023Article
- Discovery of Pharmaceutical Composition for Prevention and Treatment in Patient-Derived Metastatic Medullary Thyroid Carcinoma Model.Biomedicines · 2022Article
- RET kinase inhibitors forTherapeutic advances in medical oncology · 2022Review
- Thyroid Cancer and COVID-19: Prospects for Therapeutic Approaches and Drug Development.Frontiers in endocrinology · 2022Review
- Update on Targeted Therapy in Medullary Thyroid Cancer.Frontiers in endocrinology · 2021Review
- Medullary Thyroid Cancer - Feature Review and Update on Systemic Treatment.Acta clinica Croatica · 2020Review
- Bone metastases in thyroid cancer.Journal of bone oncology · 2020Review
- Modern surgery for advanced thyroid cancer: a tailored approach.Gland surgery · 2020Review
- Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond.Endocrine reviews · 2019Review
- Navigating Systemic Therapy in Advanced Thyroid Carcinoma: From Standard of Care to Personalized Therapy and Beyond.Journal of the Endocrine Society · 2018Review
- Surgical management of medullary thyroid carcinoma.Updates in surgery · 2017Review
- MiR-182 promotes cancer invasion by linking RET oncogene activated NF-κB to loss of the HES1/Notch1 regulatory circuit.Molecular cancer · 2017Article
- Recent Updates on the Management of Medullary Thyroid Carcinoma.Endocrinology and metabolism (Seoul, Korea) · 2016Review
- Unusual gastric mucosal infiltration by a medullary thyroid carcinoma: a case report.Journal of medical case reports · 2016Article
- The cAMP analogs have potent anti-proliferative effects on medullary thyroid cancer cell lines.Endocrine · 2016Article
- Efficacy of the Natural Clay, Calcium Aluminosilicate Anti-Diarrheal, in Reducing Medullary Thyroid Cancer-Related Diarrhea and Its Effects on Quality of Life: A Pilot Study.Thyroid : official journal of the American Thyroid Association · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
contextMedullary thyroid cancer (MTC) is a rare form of thyroid cancer comprising approximately 4% of all thyroid cancers. The majority of patients have a relatively good prognosis; however, a subgroup of patients will require systemic therapy. Large phase III randomized trials led to the approval of two drugs--vandetanib and cabozantinib--for progressive or symptomatic MTC. The decision regarding which drug to initiate first is not entirely clear and is a common concern amongst treating physicians. EVIDENCE ACQUISITION AND SYNTHESIS: A review of the literature in English was conducted, and data were summarized and integrated into a decision matrix.
conclusionsThe decision regarding which drug to initiate first for progressive MTC should be based on a careful review of the medical history, physical examination findings, medication list, electrocardiogram, laboratory results, and tumor characteristics. It is necessary to consider the relative contraindications when choosing which drug to initiate first.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.